Oncopeptides AB Reports Q3 2026 Financial Results

Oncopeptides AB reported Q3 2026 sales of SEK 28.5 million, up 41% year over year. Its gross margin was 98% for the first nine months of 2026. The company cited Pepaxti’s expansion into third-line treatment and glioblastoma proof-of-concept studies as growth catalysts, and continues to target positive commercial cash flow by 2027.